{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:32Z","timestamp":1791559472579,"version":"4.3.4"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7265-26","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:12:01Z","timestamp":1787609521000},"source":"Crossref","is-referenced-by-count":1,"title":["Systemic AA Amyloidosis Following Immune Checkpoint Inhibitor Therapy for Lung Carcinosarcoma: An Autopsy Case and Review of the Literature"],"prefix":"10.2169","author":[{"given":"Shinobu","family":"Onishi","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Hokkaido University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuaki","family":"Shoji","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Center for Cause of Death Investigation, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Matsuno","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Hokkaido University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Hokkaido University Hospital, Japan"},{"name":"Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Papa R, Lachmann HJ. Secondary AA amyloidosis. Rheum Dis Clin North Am 44: 585-603, 2018.","DOI":"10.1016\/j.rdc.2018.06.004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tada S, Iida M, Yao T, et al. Chronic intestinal pseudo-obstruction. Gut : 1412-1417, 1993.","DOI":"10.1136\/gut.34.10.1412"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sai Y, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery 152: 397-402, 2012.","DOI":"10.1016\/j.surg.2012.05.007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 6: 196-211, 2017.","DOI":"10.21037\/tlcr.2017.03.01"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 265: 621-636, 1990.","DOI":"10.1042\/bj2650621"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mo H, Yau D, Mirshahidi H, et al. AA amyloidosis associated with pulmonary squamous cell carcinoma treated with chemoradiation and immune checkpoint inhibitor therapy. Pathol Int 70: 303-305, 2020.","DOI":"10.1111\/pin.12918"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ullah N, Bin Naeem S, Jhatial MA, et al. Acute tubulointerstitial nephritis and secondary renal amyloidosis: a rare complication of atezolizumab. Cureus 15: e49533, 2023.","DOI":"10.7759\/cureus.49533"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Palamaris K, Alexandris D, Stylianou K, et al. Immune checkpoint inhibitors-associated renal toxicity: a series of 12 cases. J Clin Med 11: 4786, 2022.","DOI":"10.3390\/jcm11164786"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lapman S, Whittier WL, Parikh R, et al. Immune checkpoint inhibitor-associated renal amyloid A amyloidosis: a case series and review of the literature. J Onco-Nephrol 4: 52-58, 2020.","DOI":"10.1177\/2399369320907598"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7: 2, 2019.","DOI":"10.1186\/s40425-018-0478-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Westermark GT, F\u00e4ndrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 10: 321-344, 2015.","DOI":"10.1146\/annurev-pathol-020712-163913"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer 6: 56, 2018.","DOI":"10.1186\/s40425-018-0343-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO Global Pharmacovigilance Database. Front Pharmacol 11: 557, 2020.","DOI":"10.3389\/fphar.2020.00557"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. McKeown DJ, Brown DJ, Kelly A, et al. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 91: 1993-1995, 2004.","DOI":"10.1038\/sj.bjc.6602248"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tay SH, Toh MMX, Thian YL, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol 13: 807050, 2022.","DOI":"10.3389\/fimmu.2022.807050"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Liu TH, Chen SC, Rau KM, et al. Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma, with emphasis on locoregional therapy for oligoprogression. Liver Cancer 13: 509-521, 2024.","DOI":"10.1159\/000536549"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356: 2361-2371, 2007.","DOI":"10.1056\/NEJMoa070265"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hunter J, McGregor L. Do inflammatory rheumatic diseases still cause as much harm through amyloidosis? Amyloid 18: 208-210, 2011.","DOI":"10.3109\/13506129.2011.574354078"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7265-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:31:42Z","timestamp":1787974302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7265-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7265-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7265-26"}}